Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp


Kisqali, Ribociclib,   is used to treat postmenopausal women with locally advanced or metastatic breast cancer, that is HR positive and HER2 negative, in combination with a non-steroidal aromatase inhibitor, as initial endocrine based-therapy.

Therapeutic group: Cyclin-dependent kinase enzyme inhibitors. Kisqali contains the active ingredient ribociclib, which belongs to a group of medicines called cyclin-dependent kinase (CDK) inhibitors. Kisqali works by blocking proteins called cyclin-dependent kinases 4 and 6, which are important for the growth and division of cells. Blocking these proteins can slow down the growth of cancer cells and delay the progression of the cancer.

To Read More>>

To get a personal free assessment to our service please in fill in your details and we will get back to you shortly

Improve therapeutic outcomes, prolong life and quality of life are our main business. We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics

Close Menu